A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma

350 new cases of hepatocellular carcinoma (HCC) are diagnosed in Denmark each year, but the overall prognosis is poor with a 1-year survival rate of less than 40% and a 5-year survival rate of 10% for the entire patient group.

This national phase II non-randomized single-arm study of proton therapy in HCC is conducted with the aim to offer a safe and efficient radiation treatment to fragile patients with reduced dose to the normal liver compared to conventional photon-based radiotherapy.

Study Overview

• Status: Recruiting
• Conditions: Hepatocellular Carcinoma
• Intervention / Treatment: Radiation: Proton therapy

Detailed Description

Each year, approximately 350 new cases of hepatocellular carcinoma (HCC) are diagnosed in Denmark, but the overall prognosis is poor with a 1-year survival rate of less than 40% and a 5-year survival rate of 10% for the entire patient group.

This national phase II non-randomized single-arm study of proton therapy in HCC is conducted with the aim to offer a safe and efficient radiation treatment to fragile patients with reduced dose to the normal liver compared to conventional photon-based radiotherapy. The study aims to offer curative treatment to a larger group of patients and thus better prognosis for these patients.

The study will include 50 patients enrolled within 3 years. Patients cannot be guaranteed any direct personal benefits of participating in the trial. Participating in the study can help with new knowledge that can benefit future patients with similar illness.

The treatment will be given at the Danish Center for Particle Therapy. During radiotherapy, additional CT scans will be performed weekly as part of quality assurance until it can be documented that there is no such need.

Participation in the study will also mean additional examinations and questionnaires at the start of treatment, below treatment and at follow-up.

All patients will be asked to supply blood samples to analyze for circulating tumor DNA.

• Study Type: Interventional
• Enrollment (Anticipated): 50
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Britta Weber, MD PhD; Phone Number: +4526236694; Email: britta.weber@auh.rm.dk
• Study Contact Backup: Name: Hanna R Mortensen, Md PhD; Phone Number: +45 92432382; Email: hanna.mortensen@auh.rm.dk

Study Locations

• Denmark
  • Hovedstaden
    • Herlev, Hovedstaden, Denmark, 2730
      • Recruiting
      • Herlev Hospital
      • Contact: Mette van Overeem Felter, MD; Email: mette.van.overeem.felter@regionh.dk
      • Contact: Kirsten Vistisen, MD; Email: Kirsten.Vistisen@regionh.dk
  • Midtjylland
    • Aarhus, Midtjylland, Denmark, 8200
      • Recruiting
      • Aarhus University Hospital
      • Contact: Hanna R Mortensen, Md PhD; Phone Number: +45 92432382; Email: hanna.mortensen@auh.rm.dk
      • Contact: Britta Weber, MD PhD; Phone Number: +45 26236694; Email: britta.weber@auh.rm.dk
      • Principal Investigator: Hanna R Mortensen, MD
      • Principal Investigator: Britta Weber, MD
      • Sub-Investigator: Morten Høyer, MD
      • Sub-Investigator: Gerda E Villadsen, MD
      • Sub-Investigator: Peter Jepsen, MD
      • Sub-Investigator: Esben Worm
      • Sub-Investigator: Elizaveta Tabeksblat, MD
  • Syd
    • Odense, Syd, Denmark, 5000
      • Not yet recruiting
      • Odense University Hospital
      • Contact: Merete Krogh; Email: Merete.Krogh@rsyd.dk
      • Contact: Annette Fialla

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with HCC based on classical radiologic findings as defined by the American Association for the Study of Liver Diseases (AASLD) criteria or verified by biopsy
• No extra-hepatic disease
• Deemed ineligible for resection or Radiofrequency Ablation (RFA), or the patients should refuse RFA or surgery
• Age ≥ 18 years
• Performance status ≤ 2
• Total diameter of tumor(s) ≤ 12 cm and a maximum of 3 tumors
• Adequate liver function as measured by Child-Pugh score (Child-Pugh score ≤ 8), or absence of cirrhosis
• Has recovered adequately from toxicity and/or complications from any previous local interventions
• Patients with past or ongoing hepatitis C infection are allowed, but treatment for hepatitis C must have been completed one month before study entry
• Patients with hepatitis B infection is allowed if antiviral therapy have been given for at least 4 weeks and Hepatitis B Virus (HBV) viral load is less than 100 IU/ml. The active therapy must continue throughout the radiation therapy. Patients who are Total hepatitis B core antibody (anti-HBc)(+), negative for Hepatitis B surface antigen (HbsAg) and negative or positive for Hepatitis B surface antibody (anti-HBs) with a HBV viral load under 100 IU/mL do not require HBV anti-viral prophylaxis

• Adequate organ function

  • hematological: hemoglobin ≥ 6 mmol/l, absolute neutrophil count (ANC) ≥ 1,5 x 109/L, platelets ≥ 50 x 109/L
  • hepatic: bilirubin ≤ 1.5 x ULN, alanin-aminotransferase (ALAT) ≤ 1.5 x ULN
  • renal: creatinine ≤ 1.5 x ULN
• Ability to adhere to procedures for study and follow-up
• Signed informed consent to participate
• Final decisions on inclusion and treatment with proton therapy are at the discretion of the investigator

Exclusion Criteria:

• Previous x-ray-based radiotherapy in the liver
• Child Pugh score >8
• Tumor less than 1 cm from any critical organs at risk (OAR) (duodenum, kidney, stomach, intestines).
• Previous Selective internal radiation therapy (SIRT)
• Episode of hepatic encephalopathy within the last 6 months
• Uncontrolled ascites with need for drainage > 1 per month
• Episode of bleeding esophageal varices within the past month. If active bleeding from esophageal varices has occurred, a gastroscopy should be performed 4 weeks after the bleeding episode to ensure maximum grade 1 varices.
• Patients with metal implants where beam entrance through the metal implants cannot be avoided (not applicable for fiducial markers implanted for radiotherapy use)
• Patients for whom it is not possible to produce a robust treatment plan following the technical guidelines (Appendix A)
• Patients for whom it is not possible to implant fiducial markers e.g. due to insufficient coagulation of the blood.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Proton Arm; All patients in the study will receive proton therapy with 67.5 Gray/15 fractions(fx) /5fx per week .	Radiation: Proton therapy; All patients will receive proton therapy 67.5Gy/15fx

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of deaths of any cause	Death of any cause	4 months after start of radiotherapy
Number of participants with Radiation-induced liver disease (RILD)	Worsening of the Child- Pugh score ≥2 or alanin-aminotransferase (ALAT) ≥5 upper normal limit (ULN)	4 months after start of radiotherapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with RILD within 6 months of start of radiotherapy	Worsening of the Child- Pugh score ≥2 or ALAT ≥5 ULN	6 months after start of radiotherapy
Acute toxicity	Number of participants with Acute radiation-related toxicity grade 3 or higher measured by CTCAE v5.0	4 months after start of radiotherapy
Late toxicity	Number of participants with Late radiation-related toxicity grade 3 or higher measured by CTCAE v5.0	from 4 months until 60 months after start of radiotherapy
Radiation-induced hospitalization	Number of days spend in the hospital due to radiotherapy toxicity	within 4 months after start of radiotherapy
Health-related Quality of Life C30	Health-related Quality of life measured by the EORTC QoL questionnaires C30	Until 60 months after start of radiotherapy
Quality of Life HCC-18	Health-related Quality of life measured by the EORTC QoL questionnaires HCC18	Until 60 months after start of radiotherapy
Local control	1- and 3-year local control	3 years after start of radiotherapy
Progression-free survival	1- and 3-year progression-free survival	3 years after start of radiotherapy
Overall survival	1- and 3-year overall survival	3 years after start of radiotherapy
Pattern of failure	Pattern of failure will be reported as number of patients with in-field failures in the clinical target volumen (CTV), in-field failures in the planning target volume (PTV), and out-of-field failures.	Until 5 years after start of radiotherapy
Technical feasibility	the proportion of patients where it was possible to adhere to the guidelines of CTV dose coverage and tolerable normal tissue dose	up to 5 years
Reduction in mean liver dose	calculated on a per patient basis, and median (and inter-quartile ranged) will be reported for the study population.	up to 5 years

Collaborators and Investigators

• Sponsor: University of Aarhus
• Collaborators: Odense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; University of Leeds; Herlev Hospital
• Investigators: Principal Investigator: Britta Weber, MD PhD, Danish Center of Particle Therapy

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2022
• Primary Completion (Anticipated): December 31, 2025
• Study Completion (Anticipated): January 1, 2030

Study Registration Dates

• First Submitted: December 13, 2021
• First Submitted That Met QC Criteria: January 21, 2022
• First Posted (Actual): January 24, 2022

Study Record Updates

• Last Update Posted (Estimate): May 11, 2023
• Last Update Submitted That Met QC Criteria: May 10, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular
• Other Study ID Numbers: DCPT HCC

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No